Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 682 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
14 Results
Effects of Hepatic Ultrasound on Metabolic Homeostasis
- Liver
- Obesity & Weight Management
- Gender:All Genders
- Age:18 years - 60 years
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
- Alzheimer's
- Gender:All Genders
- Age:50 years - 85 years
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
- Leukemia & Hematologic Cancers
- Pediatric Cancers
- Gender:All Genders
- Age:21 years and younger
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- Leukemia & Hematologic Cancers
Setrusumab vs bisphosphonates in children from 2 to < 7 years old with osteogenesis imperfecta (OI)
- Genetics
Testing Atezolizumab with Selinexor in People ≥ 12 Years Old with Alveolar Soft Part Sarcoma, The AXIOM Trial
- Sarcoma Cancers
A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML
- Leukemia & Hematologic Cancers
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Gynecological Cancers
- Gender:Female only
- Age:18 years and older
Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy
- Lung Cancer
SELECT: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-Positive, HER2- Negative Breast Cancer With a Combination Regimen of Ribociclib and Optimized Endocrine Therapy
- Breast Cancer
1-10 of 14 Results